In this study, researchers are investigating the use of 186RNL (Rhenium-186 Nanoliposome) in the treatment of recurrent glioma, a rare form of central nervous system (CNS) cancer. 186RNL is delivered through a method called convection-enhanced delivery (CED), allowing for precise tumor targeting. The study provides updated results from the ongoing ReSPECT-GBM trial, comparing them to real-world data (RWD) for recurrent glioma patients.
The Phase 1 portion of the trial included 21 adult recurrent glioma patients across six dose cohorts, with 186RNL administered via CED. The treatment was well-tolerated, and the median overall survival for patients receiving a high absorbed radiation dose (>100 Gy) was 30 months. Statistical analyses revealed correlations between treatment outcomes and factors such as absorbed dose and the percentage of the tumor treated.
Comparison with RWD controls showed that 186RNL treatment had favorable overall survival compared to historical controls. The study is currently enrolling patients for Phase 1 and Phase 2 trials, with a focus on larger tumors in the Phase 1 dose-escalation phase and smaller tumors in Phase 2.
In summary, this study explores the potential of 186RNL in treating recurrent glioma and highlights its promising outcomes in terms of tolerability and overall survival when compared to real-world data.
Shreya Prakash
Clinical Research Coordinator
& Patient Navigator
The EndBrainCancer Initiative
shreya@endbraincancer.org
425-436-8688
16150 NE 85th St., Suite #201
Redmond, WA 98052
endbraincancer.org
